SCHEMBL1626544

SCHEMBL1626544

COC(=O)Cc1cccc(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.48
IDO1 P14902 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
TTR P02766 1/20 0.44
CYP2C9 P11712 1/20 0.44
TBXA2R P21731 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
P2RX7 Q99572 2/20 0.44
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7624852 0.88 IDO1 (0.47) PNMTIDO1SMN1; SMN2KDM4EKMT2A
SCHEMBL872658 0.87 NPC1 (0.52) SMN1; SMN2KDM4EKMT2AMEN1USP2
SCHEMBL29498164 0.87 NPC1 (0.52) SMN1; SMN2KDM4EKMT2AMEN1USP2
SCHEMBL16112452 0.86 ALDH1A1 (0.46) SMN1; SMN2KDM4EKMT2AUSP2LMNA
SCHEMBL11267255 0.84 SMN1; SMN2 (0.43) SMN1; SMN2KDM4EKMT2AUSP2LMNA
SCHEMBL17398610 0.84 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EKMT2AUSP2LMNA
SCHEMBL30296851 0.84 SMN1; SMN2 (0.47) SMN1; SMN2KDM4EKMT2AUSP2LMNA
SCHEMBL11359843 0.84 TAAR1 (0.49) PNMTIDO1SMN1; SMN2KMT2AMEN1
SCHEMBL5903219 0.84 KDM4E (0.43) SMN1; SMN2KDM4EKMT2AMEN1CYP2C9
SCHEMBL22969910 0.83 KMT2A (0.46) SMN1; SMN2KMT2AUSP2LMNATTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2024-09-12 US disclosed
EP-4352049-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Avelos Therapeutics Inc. (KR) 2024-04-17 EP disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 CN disclosed
WO-2022260441-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2022-12-15 WO disclosed
EP-2061779-B1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INT (DE) 2013-11-06 EP disclosed
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
EP-0714917-A2 Method of removing catalyst from ethylene-alpha-olefin copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-06-05 EP disclosed
EP-0651016-A1 Polyphenylene ether thermoplastic resin composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-05-03 EP disclosed
EP-0346098-B1 Copolymers of ethylene and an alpha-olefin and catalytic production thereof SUMITOMO CHEMICAL CO (JP) 1993-11-10 EP disclosed
US-5245007-A Basification, oxidation SUMITOMO CHEMICAL CO., LTD. (JP) 1993-09-14 US disclosed
EP-0490672-A2 Method of removing catalyst from ethylene-alpha-olefin copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1992-06-17 EP disclosed
US-5082908-A Vanadium oxyhalide-aluminum-ester complex catalyst SUMITOMO CHEMICAL CO., LTD. (JP) 1992-01-21 US disclosed
EP-0346098-A2 Copolymers of ethylene and an alpha-olefin and catalytic production thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-12-13 EP disclosed
EP-0044119-B1 PROCESS FOR THE PREPARATION OF COPOLYMERS OF ETHYLENE WITH AT LEAST ONE OTHER 1-ALKENE STAMICARBON B.V. (NL) 1985-05-29 EP disclosed
US-4435552-A COORDINATION CATALYST CONTAINING HALOACYL COMPOUND STAMICARBON B.V. (NL) 1984-03-06 US disclosed
EP-0044119-A2 Process for the preparation of copolymers of ethylene with at least one other 1-alkene STAMICARBON B.V. (NL) 1982-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN PNMT 1403/4885IDO1 777/4885SMN1; SMN2 3976/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN PNMT 1403/4885IDO1 777/4885SMN1; SMN2 3976/4885
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS MAST1, MAST3, MAST4 PNMT 1574/4885IDO1 3658/4885SMN1; SMN2 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.